021-51111890
购物车（）
sales@molnova.cn
Sulfopin
CAS No. 2451481-08-4
Sulfopin ( PIN1-3 )
产品货号. M24127 CAS No. 2451481-08-4
Sulfopin 是 Pin1 的高选择性共价抑制剂，表观 Ki 为 17nM。 Sulfopin 可在体内阻断 Myc 驱动的肿瘤。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥430 | 有现货 |
|
| 5MG | ￥749 | 有现货 |
|
| 10MG | ￥1207 | 有现货 |
|
| 25MG | ￥2437 | 有现货 |
|
| 50MG | ￥3683 | 有现货 |
|
| 100MG | ￥5085 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥824 | 有现货 |
|
生物学信息
-
产品名称Sulfopin
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Sulfopin 是 Pin1 的高选择性共价抑制剂，表观 Ki 为 17nM。 Sulfopin 可在体内阻断 Myc 驱动的肿瘤。
-
产品描述Sulfopin is a highly selective covalent inhibitor of Pin1 with an apparent Ki of 17nM. Sulfopin blocks Myc-driven tumors in vivo.
-
体外实验Cell Proliferation Assay Cell Line:Kuramochi, MDA-MB-468, NGP, NBL-S, MDA-MB-468 cells Concentration:1, 2.5 μM Incubation Time:4,6, 8 days Result:Showed variation in antiproliferative effects across cancer cell lines Kuramochi, MDA-MB-468, NGP and NBL-S, with the most pronounced sensitivity observed in MDA-MB-468 cells.
-
体内实验——
-
同义词PIN1-3
-
通路Others
-
靶点Other Targets
-
受体Pin1
-
研究领域——
-
适应症——
化学信息
-
CAS Number2451481-08-4
-
分子量281.8
-
分子式C11H20ClNO3S
-
纯度>98% (HPLC)
-
溶解度DMSO : 90 mg/mL (319.38 mM; Need ultrasonic)
-
SMILESO=C(N(CC(C)(C)C)C(CC1)CS1(=O)=O)CCl
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
Luvadaxistat
TAK-831 是一种高度选择性和有效的 D-氨基酸氧化酶 (DAAO) 抑制剂并且可以用于精神分裂症的研究。
-
Exo-1
3-(4-氟苯甲酰基)-6-甲基-2-吡啶甲酸甲酯 是一种化合物。
-
Chitinase, Serratia ...
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer).
